Global Bi-Specific Antibodies Therapy Market Growth (Status and Outlook) 2023-2029

Global Bi-Specific Antibodies Therapy Market Growth (Status and Outlook) 2023-2029

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.
LPI (LP Information)' newest research report, the “Bi-Specific Antibodies Therapy Industry Forecast” looks at past sales and reviews total world Bi-Specific Antibodies Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Bi-Specific Antibodies Therapy sales for 2023 through 2029. With Bi-Specific Antibodies Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bi-Specific Antibodies Therapy industry.
This Insight Report provides a comprehensive analysis of the global Bi-Specific Antibodies Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bi-Specific Antibodies Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bi-Specific Antibodies Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bi-Specific Antibodies Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bi-Specific Antibodies Therapy.
The global Bi-Specific Antibodies Therapy market size is projected to grow from US$ 3195 million in 2022 to US$ 17390 million in 2029; it is expected to grow at a CAGR of 27.4% from 2023 to 2029.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.
North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Bi-Specific Antibodies Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Fragment-Based Antibodies
IgG-Based Antibodies
Segmentation by application
Cancer
Haemophilia
Other Non-Cancer Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.